MedGuide=REMS? Not Always
This article was originally published in RPM Report
Executive Summary
FDA and stakeholders agree that MedGuide-only REMS are more trouble than they are worth. The agency has already told two sponsors that they don't need a REMS even though they need a MedGuide--but only because there are other products in the class that don't have REMS.
You may also be interested in...
REMS 2.0: FDA Refining New Drug Safety Tools
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
REMS 2.0: FDA Refining New Drug Safety Tools
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
Cymbalta for Fibromyalgia: The REMS That Wasn't
FDA will not necessarily require a formal Risk Evaluation & Mitigation Strategy for drugs that already have mandatory consumer medication guides. That means Lilly has a freer hand to compete against Lyrica in an important new market--and now the question becomes what FDA might do to impose tighter controls on the Pfizer brand.